(CercleFinance.com) – Valneva announces positive early Phase III safety data in adolescents for its single-dose chikungunya vaccine candidate, VLA1553, data from the ongoing VLA1553-321 trial in Brazil .
According to this clinical trial, conducted in an endemic area and including participants previously infected with the chikungunya virus, VLA1553 was generally safe and well tolerated in 12 to 17 year olds, whether or not they had been previously infected with the virus.
VLA1553-321 is conducted with the aim of being able to apply, if successful, for an extension of use for this age group if VLA1553 is first authorized in adults by the American FDA, authorization currently being subject to priority review.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
